Document Detail

The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
MedLine Citation:
PMID:  23385859     Owner:  NLM     Status:  In-Data-Review    
PURPOSE OF REVIEW: Treatment of advanced nonsmall cell lung cancer (NSCLC) has rapidly changed over the last decade. On the basis of the progress made in cancer biology, the old-fashioned 'one size fits all' chemotherapeutic approach is shifting to a novel approach in which treatment choice is mainly based on the tumor's biological genotype. The aim of the present review is to describe the anaplastic lymphoma kinase (ALK) translocation as a prominent molecular driver aberration in NSCLC, its prognostic and predictive role, and the new available treatment options.
RECENT FINDINGS: Crizotinib is a tyrosine kinase inhibitor of MET, ALK and ROS1. Its impressive clinical activity shown in a phase IB trial led to accelerated approval for patients with ALK-positive advanced NSCLC. More recently, a phase III trial confirmed the high activity of crizotinib in this subset of lung tumors. Many new-generation ALK inhibitors are currently also in clinical development.
SUMMARY: ALK-positive NSCLC has emerged as a distinct, well defined subset of lung malignancies. The use of ALK inhibitors deeply impacts the therapy of patients harboring such translocation. Nevertheless, to date, several issues remain open, such as the most suitable screening and diagnostic method for the detection of ALK gene rearrangement and expression and particularly the mechanisms of acquired resistance for further clinical development of these agents.
Manolo D'Arcangelo; Murry W Wynes; Fred R Hirsch
Related Documents :
21124649 - Specific investigation of sample handling effects on protease activities and absolute s...
23359149 - A method for conducting highly sensitive microrna in situ hybridization and immunohisto...
23772649 - Dual-targeted nanocarrier based on cell surface receptor and intracellular mrna: an eff...
24361399 - Premature senescence in human breast cancer and colon cancer cells by tamoxifen-mediate...
24395529 - Myriocin induces apoptotic lung cancer cell death via activation of dr4 pathway.
24204899 - Twist1 promotes gastric cancer cell proliferation through up-regulation of foxm1.
7231199 - Post-menopausal bleeding: a study of more than 1000 cases.
24135859 - Reappraisal of the vascular anatomy of the colon and consequences for the definition of...
17311699 - Advanced radiation therapy technologies in the treatment of rectal and anal cancer: int...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in oncology     Volume:  25     ISSN:  1531-703X     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  121-9     Citation Subset:  IM    
aUniversity of Colorado Cancer Center, Aurora, Colorado, USA bIstituto Toscano Tumori, Civil Hospital, Livorno, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activin, neutrophils, and inflammation: just coincidence?
Next Document:  Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.